Chemomab Therapeutics

Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation with high unmet need

General Information
Company Name
Chemomab Therapeutics
Founded Year
2011
Location (Offices)
Israel +1
Founders / Decision Makers
Number of Employees
21
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Chemomab Therapeutics - Company Profile

Chemomab Therapeutics, a clinical stage biotechnology company, is focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. The company's flagship product, CM-101, a monoclonal antibody targeting the chemokine CCL24, has shown promising results in preclinical and clinical studies. With its potential to treat severe and life-threatening conditions, such as NASH and severe lung injury, CM-101 has garnered attention.

Founded in 2011 and headquartered in Israel, Chemomab recently secured a significant $45.50M Post-IPO Equity investment on 16 March 2021. The investment was led by OrbiMed, Apeiron Investment Group, Cormorant Asset Management, Presight Capital, and prominent investor Peter Thiel. This funding indicates strong support and confidence in the potential of Chemomab's pipeline and CM-101's therapeutic efficacy.

Overall, Chemomab Therapeutics stands at the forefront of addressing unmet medical needs in fibro-inflammatory diseases, backed by substantial financial support and a promising developmental trajectory for CM-101.

Taxonomy: therapeutics, fibro-inflammatory diseases, clinical stage, monoclonal antibody, CCL24, fibrosis, inflammation, NASH, lung injury, primary sclerosing cholangitis, clinical trials, biomarker study, drug development

Funding Rounds & Investors of Chemomab Therapeutics (5)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $10.00M 3 Sphera Global Healthcare Fund 25 Jul 2024
Post-IPO Equity $45.50M 5 Peter Thiel 16 Mar 2021
Series C $20.00M 2 01 Dec 2019
Series B $10.00M - 04 Dec 2017
Series A $5.00M - 03 Sep 2016

Latest News of Chemomab Therapeutics

View All

No recent news or press coverage available for Chemomab Therapeutics.

Similar Companies to Chemomab Therapeutics

View All
Upstream Bio - Similar company to Chemomab Therapeutics
Upstream Bio Developing treatments for inflammatory diseases
Molecure - Similar company to Chemomab Therapeutics
Molecure Fate can be altered.
Molecure - Similar company to Chemomab Therapeutics
Molecure Fate can be altered.